Beneficial effects of Tau-specific autophagic degraders could be extended to iPSC-derived neuronal cells from a sporadic AD patient, suggesting potential therapeutic value of selective autophagic degradation of Tau for treatment of human AD. The gene discussed is MAPT; the disease is Alzheimer disease.